BioIVT, a provider of research models and services for drug development, has announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
Transport proteins (transporters) govern drug uptake and disposition, and hence drug concentration, in the blood and vital organs such as the liver, kidney, heart, lungs, and brain. As a result, transporter effects are evaluated early in the lead candidate selection and optimization process in drug R&D programs.
BioIVT’s portfolio now includes all of Optivia’s products, including its Opti-Expression™ technology, Opti-TargetTM, Opti-DDI™, and Opti-ADME™ Transporter Services Panels, and its TransFlex™ Single Transporter and Multi-Transporter Assay Plates.
Optivia’s Opti-Expression technology allows rapid, robust and consistent expression of various transporters in polarised mammalian cell monolayers with much greater scalability and flexibility than is possible with stably transfected cell lines.
Optivia’s Opti-Target Transporter Services Panel consists of a wide variety of validated and novel transporter targets implicated in diseases, toxicity, and tissue targeting. Its Opti-ADME Transporter Services Panel consists of major transporters that affect ADME properties of a variety of drugs. Studying them provides a better understanding of drug bioavailability, tissue distribution, excretion, and inter-individual variability in drug responses.
Optivia’s staff will join BioIVT’s PHASEZERO® Research Services team and provide a full range of transporter services, including screening studies for lead discovery and optimization, profiling and mechanism of action studies for lead selection, and other studies to support regulatory submissions.
BioIVT Chief Executive Officer Jeffrey Gatz said,“We are delighted that Optivia is joining BioIVT as we position to become the world leader in transporter sciences. Optivia will be an important addition to BioIVT’s leading ADME-Toxicology model systems franchise, complementing the capabilities of our recent acquisitions of Qualyst Transporter Solutions and Ascendance Biotechnology.”
Optivia Founder, President and CEO Yong Huang, PhD said, “We look forward to joining BioIVT and being able to offer our customers a broader range of products and services but with the same high quality, attention to detail, and excellent customer service that they have learned to expect from Optivia.”